Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that its portfolio company BioreclamationIVT has acquired Chestertown, Maryland-based ILSbio, a commercial biobank and molecular laboratory established to accelerate research and discovery. Terms of the transaction were not disclosed.
Founded in 1996, ILSbio provides well-characterized human specimens and laboratory services to support researchers in the development of diagnostics, prognostics, and therapeutics for cancer and a wide range of other diseases.
Bob Dunn, Managing Director of TSCP said, “ILSbio enhances the BioreclamationIVT range by providing a wide array of specimen types, including matched sets of normal and diseased tissue, FFPE, blood, and serum, focusing primarily on cancer.” Said Mr. Dunn, “Adding this new expertise to the Bioreclamation platform gives us greatly increased capabilities to serve researchers globally. We’re pleased to have the opportunity to help ILSbio make its growth goals a reality.”
